Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases

PCSK9 inhibition is a new powerful cholesterol-lowering strategy. Recently, it was reported that CETP inhibitors influence PCSK9 levels as an off-target effect. We explored the relationship between circulating...

Source: Cardiovascular Diabetology - August 4, 2016 Category: Cardiology Authors: Josefa Girona, Daiana Ibarretxe, Nuria Plana, Sandra Guaita-Esteruelas, Nuria Amigo, Mercedes Heras and Luis Masana Source Type: research